October 22nd 2024
The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.
FDA Committee Recommends Approval for Rebyota (RBX2660) to Treat Recurrent C Difficile
September 22nd 2022The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
Read More